拉米夫定联合阿德福韦酯治疗老年失代偿期乙肝后肝硬化临床疗效探讨.docVIP

拉米夫定联合阿德福韦酯治疗老年失代偿期乙肝后肝硬化临床疗效探讨 　　[摘要] 目的 研究分析拉米夫定与阿德福韦酯联合治疗老年失代偿期乙肝后肝硬化的临床疗效。方法 整群选取2014年12月―2015年12月期间在该院进行诊治的136例老年失代偿期乙肝后肝硬化患者，通过随机数字双盲法进行平均分组，各68例。对照组采用拉米夫定治疗；试验组采用拉米夫定联合阿德福韦酯联合治疗，对比分析两组患者 HBV DNA 阴转率、肝功能指标。结果 试验组患者 HBV DNA 阴转率85.29%（58/68）显著高于对照组的55.88%（38/68），差异有统计学意义（P0.05）。治疗后，试验组患者不同时段肝功能指标明显优于对照组，差异有统计学意义（P0.05）。 结论 拉米夫定联合阿德福韦酯联合治疗老年失代偿期乙肝后肝硬化，可迅速抑制病毒，使肝功能得到明显改善，具有较高的应用及推广价值。 　　[关键词] 拉米夫定；阿德福韦酯；老年；乙肝肝硬化；疗效 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2016）03（b）-0113-02 　　[Abstract] Objective To research and analyze the clinical curative effect of lamivudine combined with adefovir dipivoxil in treatment of decompensation stage of posthepatitic cirrhosis in elderly. Methods 136 cases of elderly patients with decompensation stage of posthepatitic cirrhosis diagnosed and treated in our hospital from December 2014 to December 2015 were selected and randomly divided into two groups with 68 cases in each， the control group were treated with lamivudine， the test group were treated with lamivudine combined with adefovir dipivoxil， the negative conversion rate of HBV and DNA and liver function indexes of the two groups were compared and analyzed. Results The negative conversion rate of HBV and DNA in the test group was obviously higher than that in the control group，85.29% （58/68） vs 55.88% （38/68） and the difference was statistically significant P0.05， after treatment， the liver function indexes at different periods in the test group were obviously better than those in the control group， and the differences were statistically significant P0.05. Conclusion Lamivudine combined with adefovir dipivoxil in treatment of？decompensation stage of posthepatitic cirrhosis in elderly can rapidly inhibit virus and obviously improve the liver function， which is of higher application and promotion value. 　　[Key words] Lamivudine； Adefovir dipivoxil； Elderly； Hepatitic cirrhos； Curative effect 　　失代偿期乙肝后肝硬化还没有特别有效的抗病毒治疗措施[1]。抗病毒治疗能够延缓病情的发展，延长患者的生存时间。应用干扰素治疗后，一些患者可能出现肝炎发作，或是病情继续加